留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

脐血移植临床应用30年的回顾及展望

孙自敏

孙自敏. 脐血移植临床应用30年的回顾及展望[J]. 器官移植, 2020, 11(2): 199-203. doi: 10.3969/j.issn.1674-7445.2020.02.004
引用本文: 孙自敏. 脐血移植临床应用30年的回顾及展望[J]. 器官移植, 2020, 11(2): 199-203. doi: 10.3969/j.issn.1674-7445.2020.02.004
Sun Zimin. Review and prospect of clinical application of umbilical cord blood transplantation for 30 years[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 199-203. doi: 10.3969/j.issn.1674-7445.2020.02.004
Citation: Sun Zimin. Review and prospect of clinical application of umbilical cord blood transplantation for 30 years[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 199-203. doi: 10.3969/j.issn.1674-7445.2020.02.004

脐血移植临床应用30年的回顾及展望

doi: 10.3969/j.issn.1674-7445.2020.02.004
基金项目: 

国家自然科学基金面上项目 81470350

中央高校基本科研业务费专项资金 WK9110000001

详细信息
    作者简介:

    孙自敏,中国科学技术大学附属第一医院血液科主任医师、二级教授、江淮名医、享受国务院特殊津贴、安徽省学术技术带头人、安徽省立医院造血干细胞移植首席专家、安徽省115产业创新团队“造血干细胞移植”带头人。专业特长为造血干细胞移植及疑难血液病的诊治,已完成脐血造血干细胞移植1 200余例,引领中国脐血移植的发展。主持并获得国家自然科学基金等20余项科研基金的资助,发表论文200余篇,其中以第一或通讯作者发表SCI和核心期刊论文70余篇。培养研究生50余名。获得安徽省科学技术奖项10余项,多次受邀在国内外学术会议交流脐血移植的成果,参加国内造血干细胞移植相关等指南的编写。曾兼任中华医学会血液学分会常务委员,中华医学会血液学分会造血干细胞移植学组副组长等职务

  • 中图分类号: R617, R552

Review and prospect of clinical application of umbilical cord blood transplantation for 30 years

More Information
  • 摘要: 造血干细胞移植是治愈血液系统恶性肿瘤、造血衰竭性疾病和先天性遗传性代谢性疾病的重要方法。脐血是造血干细胞的主要来源之一,是干细胞研究及应用最理想的细胞来源。本文从脐血移植的历史及现状、脐血移植的优势、脐血移植技术的改进、脐血移植的应用前景及展望等方面,对脐血移植30多年的临床应用进行回顾和展望。

     

  • [1] GABELLI M, VEYS P, CHIESA R. Current status of umbilical cord blood transplantation in children[J]. Br J Haematol, 2019, DOI: 10.1111/bjh.16107[Epubahead of print].
    [2] 孙自敏, 汤宝林.我如何用单份脐血干细胞移植治疗成人恶性血液病[J].中华血液学杂志, 2019, 40(6): 449-452. DOI: 10.3760/cma.j.issn.0253-2727.2019.06.001.

    SUN ZM, TANG BL. How I treat adult malignant hematological diseases with single umbilical cord blood transplantation[J]. Chin J Hematol, 2019, 40(6): 449-452. DOI: 10.3760/cma.j.issn.0253-2727.2019.06.001.
    [3] WAGNER JE, BROXMEYER HE, BYRD RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment[J]. Blood, 1992, 79(7):1874-1881. doi: 10.1182/blood.V79.7.1874.1874
    [4] KURTZBERG J, LAUGHLIN M, GRAHAM ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients[J]. N Engl J Med, 1996, 335(3):157-166. doi: 10.1056/NEJM199607183350303
    [5] WAGNER JE, ROSENTHAL J, SWEETMAN R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease[J]. Blood, 1996, 88(3):795-802. doi: 10.1182/blood.V88.3.795.795
    [6] ROCHA V, WAGNER JE JR, SOBOCINSKI KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling[J]. N Engl J Med, 2000, 342(25):1846-1854. doi: 10.1056/NEJM200006223422501
    [7] WAGNER JE, GLUCKMAN E. Umbilical cord blood transplantation: the first 20 years[J]. Semin Hematol, 2010, 47(1):3-12. DOI: 10.1053/j.seminhematol.2009.10.011.
    [8] KÖGLER G, SENSKEN S, AIREY JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential[J]. J Exp Med, 2004, 200(2):123-135. doi: 10.1084/jem.20040440
    [9] FATOBENE G, STORER BE, SALIT RB, et al. Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation[J]. Haematologica, 2019, 104(4):835-843. DOI: 10.3324/haematol.2018.202754.
    [10] PASCAL L, TUCUNDUVA L, RUGGERI A, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation[J]. Blood, 2015, 126(8):1027-1032. DOI: 10.1182/blood-2014-09-599241.
    [11] TONG J, XUAN L, SUN Y, et al. Umbilical cord blood transplantation without antithymocyte globulin results in similar survival but better quality of life compared with unrelated peripheral blood stem cell transplantation for the treatment of acute leukemia-a retrospective study in China[J]. Biol Blood Marrow Transplant, 2017, 23(9):1541-1548. DOI: 10.1016/j.bbmt.2017.05.004.
    [12] SARVARIA A, BASAR R, MEHTA RS, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation[J]. Blood, 2016, 128(10):1346-1361. DOI: 10.1182/blood- 2016-01-695122.
    [13] HIWARKAR P, QASIM W, RICCIARDELLI I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells[J]. Blood, 2015, 126(26):2882-2891. DOI: 10.1182/blood- 2015-06-654780.
    [14] MILANO F, APPELBAUM FR, DELANEY C. Cord-blood transplantation in patients with minimal residual disease[J]. N Engl J Med, 2016, 375(22):2204-2205. http://www.ncbi.nlm.nih.gov/pubmed/27602666
    [15] SUN Z, LIU H, LUO C, et al. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: a retrospective (development) and a prospective (validation) study[J]. Int J Cancer, 2018, 143(3):699-708. DOI: 10.1002/ijc.31339.
    [16] TANG B, ZHU X, ZHENG C, et al. Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation[J]. Bone Marrow Transplant, 2019, 54(10):1614-1624. DOI: 10.1038/s41409-019-0441-4.
    [17] WU Y, LI Y, FU B, et al. Programmed differentiated natural killer cells kill leukemia cells by engaging SLAM family receptors[J]. Oncotarget, 2017, 8(34):57024-57038. DOI: 10.18632/oncotarget.18659.
    [18] DELANEY C, HEIMFELD S, BRASHEM-STEIN C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution[J]. Nat Med, 2010, 16(2):232-236. DOI: 10.1038/nm.2080.
  • 加载中
计量
  • 文章访问数:  137
  • HTML全文浏览量:  24
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-13
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-03-15

目录

    /

    返回文章
    返回